Clinical Scorecard: Long-term Outcomes for Mothers and Newborns Following Nivolumab Treatment in Metastatic Tonsillar Sarcomatoid Squamous Cell Carcinoma: A Case Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Immunotherapy with checkpoint inhibitors (ICIs) affects maternal-fetal tolerance and may impact pregnancy outcomes; further research is needed to clarify these effects.
Target Population
Care Setting
Key Highlights
Successful pregnancy and normal fetal development observed after nivolumab treatment, with detailed treatment history.
Patient experienced a near complete radiological response to nivolumab.
Breastfeeding occurred without adverse effects on child growth.
Patient developed a lung recurrence 32 months after stopping nivolumab due to pregnancy.
Limited data on the effects of ICIs on pregnancy and fertility.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Assess neonatal growth and maternal disease course following ICI cessation due to pregnancy, including specific parameters.
Risks
Patient & Prescribing Data
Nivolumab categorized as pregnancy category D; use of effective birth control recommended during and for 5 months after treatment, with implications of category D explained.
Clinical Best Practices
Avoid ICI use during pregnancy whenever possible, with emphasis on individualized patient counseling on risks associated with ICI treatment during reproductive years.
